Vium

This system, encompassing Smart Housing™, the Vium Cloud, and an online Research Suite, enabled scientists to collect continuous, high-quality digital biomarkers from research models, such as motion and breathing rates. The business model centered on providing this comprehensive platform to a client base that included biotechnology firms, pharmaceutical companies, academic institutions, and computational drug discovery labs. By automating data collection and analysis, Vium aimed to accelerate the drug development pipeline and provide deeper insights into disease progression, thereby helping researchers make better-informed decisions. The platform was noted for its low-touch approach, which fostered a more humane environment for animal subjects, earning an unprecedented commendation from AAALAC International for upholding the "3 Rs" framework for humane animal research.

Vium attracted significant investment from notable venture capital firms, including Lux Capital, Data Collective, Founders Fund, Dolby Family Ventures, and AME Cloud Ventures. A key milestone in the company's history was its acquisition by Recursion, a digital biology company, on July 28, 2020. This strategic acquisition aimed to combine Vium's in vivo dataset capabilities with Recursion's extensive in vitro datasets, enhancing the overall effort to industrialize and accelerate drug discovery. Keywords: preclinical research, in vivo studies, digital vivarium, living informatics, drug discovery, digital biomarkers, animal research, research automation, machine learning in research, computer vision, sensor technology, vivarium technology, preclinical data, humane animal research, AAALAC, bioengineering models, research suite, cloud data platform, research reproducibility, study optimization, pharmaceutical technology, biotechnology research